Sector News

Categories

Borderless Insights

Image
The Skills-Forward Revolution:   Stretching the Boundaries of Professional Flexibility
Image
Sustainability: Business Leaders Must Secure the Long-Term Strategy Despite Short-Term Pressures
Image
Negotiating Terms with a New Employer

The eyes have it as Shire parades pipeline

December 11, 2014
Life sciences
Shire, fresh from the collapse of its $55 billion takeover by AbbVie, has been touting its pipeline to investors in the USA, highlighting treatments which could contribute $3 billion in sales by 2020.
 
Speaking to investors at Shire’s US headquarters in Lexington, Massachusetts, chief executive Flemming Ornskov said that there were 22 programmes in the clinic, “the most in Shire’s history”. R&D head Philip Vickers added that “a number of significant clinical milestones [are] anticipated over the next 18 months”, saying the “highly productive internal pipeline” will be “complemented by the acquisition of external assets and innovative collaborations”.
 
Chief among these treatments is SHP607, a protein replacement therapy which has just received fast-track designation from the the US Food and Administration for the prevention of retinopathy of prematurity, a blinding eye disorder that affects premature babies. It is currently in Phase II.
 
Staying with things ocular, lifitegrast for dry eye disease will be filed in the first quarter of 2015. Shire also highlighted SHP625 for the rare genetic disorder Alagille Syndrome and SHP626  for non-alcoholic steatohepatitis, a condition characterized by fat deposits in the liver. The company also has an action date of February 1 for its attention-deficit hyperactivity disorder blockbuster Vyvanse (lisdexamfetamine dimesylate) as a potential treatment for binge eating disorder.
 
CF project
 
Shire also announced that it is receiving up to $15 million from the Cystic Fibrosis Foundation to support its messenger RNA technology platform for the disease.  
 
The company said its goal is to deliver mRNA that codes for a fully functional version of the cystic fibrosis transmembrane conductance (CFTR) protein to the lungs of CF patients. If high enough levels of functional CFTR protein can be produced, lung function may be improved.
 
By Kevin Grogan
 
Source: Pharma Times

comments closed

Related News

July 21, 2024

CordenPharma invests €900m in peptide platform expansion

Life sciences

CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.

Read more
July 21, 2024

DSM-Firmenich to sell MEG-3 fish oil business to KD Pharma Group

Life sciences

DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.

Read more
July 21, 2024

Veranova appoints Cécile Maupas as Senior Vice President, Chief Commercial Officer

Life sciences

Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.

Read more
More news

How can we help you?

We're easy to reach